ADC Therapeutics SA (ADCT)

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates

ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates PR Newswire...

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan PR Newswire LAUSANNE, Switzerland, May...

ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026

ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026 PR Newswire...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form PRE 14A - Other preliminary proxy statements